Cargando…
Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis
Reduced amplitude of mismatch negativity (MMN) is one of the more promising biological markers of schizophrenia. This finding holds true in both early and chronic phases of the disorder, and is compatible with the glutamatergic dysfunction hypothesis. To further establish MMN as a biomarker of aberr...
Autores principales: | Nagai, Tatsuya, Kirihara, Kenji, Tada, Mariko, Koshiyama, Daisuke, Koike, Shinsuke, Suga, Motomu, Araki, Tsuyoshi, Hashimoto, Kenji, Kasai, Kiyoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442101/ https://www.ncbi.nlm.nih.gov/pubmed/28536477 http://dx.doi.org/10.1038/s41598-017-02267-1 |
Ejemplares similares
-
Mismatch Negativity Predicts Remission and Neurocognitive Function in Individuals at Ultra-High Risk for Psychosis
por: Fujioka, Mao, et al.
Publicado: (2020) -
Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset
por: Koshiyama, Daisuke, et al.
Publicado: (2018) -
Mismatch Negativity as a “Translatable” Brain Marker Toward Early Intervention for Psychosis: A Review
por: Nagai, Tatsuya, et al.
Publicado: (2013) -
Reduced Auditory Mismatch Negativity Reflects Impaired Deviance Detection in Schizophrenia
por: Koshiyama, Daisuke, et al.
Publicado: (2020) -
A Predictive Coding Perspective on Mismatch Negativity Impairment in Schizophrenia
por: Kirihara, Kenji, et al.
Publicado: (2020)